I’m glad you enjoyed my joke. I thought it was pretty funny.
It’s less funny that you shamelessly prove my point and yet still soldier on. You were too lazy to look up what the filing is called? So let me get this straight: you’re so ignorant of medical devices and the markets/processes involved with them that you would have had to look up the process to get the name of the pre-marketing notice required by the company, yet you somehow know it all well enough to brazenly proclaim that there is no value at this time, and that we can assume there’s still time and money attached to the runway for achieving value? You must be superhuman, because the cognitive dissonance there makes my head want to explode. The amazing thing is that you say it all without batting an eye. What would you think of an “analyst” who had to look up a BLA to get the name right, and then assumed that there was no value in a drug because the BLA wasn’t filed yet? It’s complete nonsense dressed up as lazy analysis.
Here’s an idea. If you want to be taken seriously, do some actual analysis. Understand the 510(k) process, research the market potential of the prognostic test, learn about recent comps, find a PV, and discount accordingly like you would any other asset with future cash flows attached.
I’d say that I’ll wait... but I won’t. Last time I asked you for an example or better analysis of something (February 2019, discussing the potential cost of going it alone), the most you would offer is an anecdote about a company that used “between $50-150mm to build a sales team and continue developing its pipeline.” As if that definitively settled the matter. I expect no better from you this time. You clearly have an agenda - again, I’ll say that it must be nice to live in a jurisdiction with no capital gains tax. You get yourself in trouble when you get sloppy picking your spots in which to be disingenuous. That shouldn’t surprise anyone though... it’s not like a reputable equity shop is letting its analysts run a side hustle on blogspot to pimp OTC stocks. I tired of this board long ago, mostly due to your nonsense, so I probably won’t be back for a while to continue this conversation. I’ll just drop by now and then to remind anyone who happens to not be paying attention that you’re full of it and should be disregarded.
By the way, excellent red herring re: enrollment. It sounded good on paper, but I thought about it on my entire six hour bike ride today and still can’t come up with a single way that it applies to your (at best) blatant and willful ignorance of the medical device market.
